TY - JOUR
T1 - Impact of obesity on surgical and oncologic outcomes in ovarian cancer
AU - Kumar, Amanika
AU - Bakkum-Gamez, Jamie N.
AU - Weaver, Amy L.
AU - McGree, Michaela E.
AU - Cliby, William A.
N1 - Publisher Copyright:
© 2014 Elsevier Inc.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Objectives. The aim of this study is to determine the impact of obesity on surgical and oncologic outcomes after primary debulking surgery (PDS) in advanced epithelial ovarian cancer (EOC).Methods.Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient characteristics, intraoperative and postoperative outcomes, recurrence and status were abstracted. Complications were graded according to the 4-point Accordion classification. For analyses, patients were divided into three groups according to body mass index (BMI): group 1-BMI b25.0 kg/m 2 group 2-BMI 25.0-39.9 kg/m2 and group 3-BMI ≥40.0 kg/m2.Results. Of the 620 patients included in the study, 36.6%, 56.9%, and 6.5% were in weight groups 1, 2, and 3, respectively. Weight group 3 was an independent predictor of severe complications after adjusting for confounders (adjusted odds ratio (95% CI): 2.93 (1.38, 6.20) for group 3 vs. group 2). Weight groupwas not associatedwith differences in residual disease (p = 0.80). The 90-day mortality rates were 11.9%, 6.7%, and 15.7%, respectively, in weight group 1, 2, and 3 (p = 0.049 unadjusted, p = 0.01 adjusted). There was no difference in OS (p = 0.52) or PFS (p = 0.23) between weight groups.Conclusions. BMI ≥40.0 kg/m2 is an independent predictor of severe 30-day postoperative morbidity and 90-day mortality after PDS for EOC-information useful in preoperative counseling. BMI does not appear to impact long-term oncologic outcomes including residual disease at PDS, although we had limited power at the extremes of BMI. BMI may be an important factor to consider in risk-adjustment models and reimbursement strategies.
AB - Objectives. The aim of this study is to determine the impact of obesity on surgical and oncologic outcomes after primary debulking surgery (PDS) in advanced epithelial ovarian cancer (EOC).Methods.Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient characteristics, intraoperative and postoperative outcomes, recurrence and status were abstracted. Complications were graded according to the 4-point Accordion classification. For analyses, patients were divided into three groups according to body mass index (BMI): group 1-BMI b25.0 kg/m 2 group 2-BMI 25.0-39.9 kg/m2 and group 3-BMI ≥40.0 kg/m2.Results. Of the 620 patients included in the study, 36.6%, 56.9%, and 6.5% were in weight groups 1, 2, and 3, respectively. Weight group 3 was an independent predictor of severe complications after adjusting for confounders (adjusted odds ratio (95% CI): 2.93 (1.38, 6.20) for group 3 vs. group 2). Weight groupwas not associatedwith differences in residual disease (p = 0.80). The 90-day mortality rates were 11.9%, 6.7%, and 15.7%, respectively, in weight group 1, 2, and 3 (p = 0.049 unadjusted, p = 0.01 adjusted). There was no difference in OS (p = 0.52) or PFS (p = 0.23) between weight groups.Conclusions. BMI ≥40.0 kg/m2 is an independent predictor of severe 30-day postoperative morbidity and 90-day mortality after PDS for EOC-information useful in preoperative counseling. BMI does not appear to impact long-term oncologic outcomes including residual disease at PDS, although we had limited power at the extremes of BMI. BMI may be an important factor to consider in risk-adjustment models and reimbursement strategies.
KW - Ovarian cancer Obesity Overall survival Disease-free survival
UR - http://www.scopus.com/inward/record.url?scp=84908015585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908015585&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2014.07.103
DO - 10.1016/j.ygyno.2014.07.103
M3 - Article
C2 - 25110330
AN - SCOPUS:84908015585
SN - 0090-8258
VL - 135
SP - 19
EP - 24
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -